Lilly says manufacturing, compliance heads to retire By Reuters

© Reuters. An Eli Lilly and Company pharmaceutical manufacturing plant is pictured in Branchburg, New Jersey

(Reuters) – Drugmaker Eli Lilly (NYSE:) and Co said on Tuesday the chiefs of its manufacturing division and the ethics and compliance department will step down from their roles in the coming months.

Myles O’Neill, senior vice president and president of Lilly’s manufacturing operations, will retire in early May, after nearly two decades with the company, Lilly said.

O’Neill, 62, will be replaced by Edgardo Hernandez, who is currently senior vice president of the drugmaker’s global injectible drug product and device manufacturing division.

The drugmaker also said Chief Ethics and Compliance Officer Melissa Barnes will retire in June.

Barnes, 52, has been with the company for 26 years and will be replaced by Lilly Deputy General Counsel Alonzo Weems.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Most Related Links :
Business News Governmental News Finance News

Need Your Help Today. Your $1 can change life.

[charitable_donation_form campaign_id=57167]

Source link

Back to top button